Our center has been receiving numerous requests to look for response of GEPNET patients who started a novel somatostatin analogue. We noticed a reduction of tumoral SUV in the post- vs the pre-octreotide PET/CT. I am planning to find out a way to quantify the response rate using SUV measurement.

More Teik Hin Tan's questions See All
Similar questions and discussions